Table 2 Average effects estimated from published clinical trails by ethnicity for HMG-CoA reductase inhibitors and fibric acid derivatives
Medication | Phenotype | African Americans | Non-African Americans * | All | |||
|---|---|---|---|---|---|---|---|
|  |  | No. of pts pooled | Average effect (mg/dl) ± SE | No. of pts pooled | Average effect (mg/dl) ± SE | No. of pts pooled | Average effect (mg/dl) ± SE |
HMG-CoA reductase inhibitors | TC | 572 | -51.4 ± 11.2 | 10637 | -52.1 ± 13.2 | 16811 | -50.7 ± 13.9 |
|  | LDL-C | 572 | -47.9 ± 7.2 | 10637 | -49.9 ± 13.6 | 16811 | -48.1 ± 13.9 |
|  | HDL-C | 572 | +0.4 ± 1.7 | 10637 | +2.3 ± 0.5 | 16811 | +2.0 ± 0.8 |
|  | TG | 572 | -18.8 ± 4.2 | 10637 | -18.4 ± 3.7 | 16811 | -19.7 ± 4.5 |
Fibric acid derivatives (Gemfibrozil) | TC | - | - | 477 | -46.1 ± 8.6 | 2573 | -20.1 ± 15.3 |
|  | LDL-C | - | - | 477 | -40.1 ± 7.0 | 2573 | -11.4 ± 14.4 |
|  | HDL-C | - | - | 477 | +5.9 ± 1.8 | 2573 | +3.1 ± 1.6 |
|  | TG | - | - | 477 | -57.1 ± 14.1 | 2573 | -59.0 ± 10.4 |